Skip to content

The efficiency of continuous intrafemoral perfusion of PRP combine with the therapy of promoting blood circulation to C1 type femoral head necrosis preservation

The efficiency of continuous intrafemoral perfusion of PRP combine with the therapy of promoting blood circulation to C1 type femoral head necrosis preservation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026387
Enrollment
Unknown
Registered
2019-10-07
Start date
2019-10-20
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteonecrisis of the femoral head

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-55 years, male or female, non-traumatic femoral head necrosis; (2) X-ray of the hip joint is showing C1 type femoral head necrosis; (3) Patients with ARCO stage of ONFH who are stage II with significant pain and patients with stage IIIA with pain or limited mobility; (4) The affected femoral head did not collapse or collapsed less than 4mm, the joint space was not significantly narrow, and the head-to-head matching relationship was good; (5) The patient agrees to participate in the trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with other diseases that affect the progression of ONFH (such as major diseases of heart, lung, liver and kidney system, nephrotic syndrome, systemic lupus erythematosus, etc. still need to take hormones) and are in active period; (2) Subjects suffering from hip or surrounding fractures, infections, tumors, etc. during the trial; (3) Subjects with serious adverse reactions during the test; (4) The investigator believes that it is not appropriate to continue to participate in the subjects of this clinical trial.

Design outcomes

Primary

MeasureTime frame
Harris score;Collapse rate;Later sidewall thickness;Bone marrow edema;Femoral head cartilage thickness;Vascular evaluation;

Secondary

MeasureTime frame
VAS score;Hip mobility;SF-12 score;Blood analysis;Coagulation four;Bone metabolism index;

Countries

China

Contacts

Public ContactWei He

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

hw13802516062@163.com+86 13802516062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026